Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

Bourke, L., Kirkbride, P., Hooper, R. et al. (3 more authors) (2013) Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? British Journal of Cancer, 108 (1). pp. 9-13. ISSN 0007-0920

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2013 Cancer Research UK. Article made available via (http://creativecommons.org/licenses/by-nc-sa/4.0)
Keywords: prostate cancer; androgen deprivation; cost-effectiveness; cardiovascular risk
Dates:
  • Published: 15 January 2013
  • Accepted: 20 September 2012
  • Published (online): 29 November 2012
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Cardiovascular Science (Sheffield)
The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 09 Dec 2016 11:21
Last Modified: 09 Dec 2016 11:21
Published Version: https://doi.org/10.1038/bjc.2012.523
Status: Published
Publisher: Cancer Research UK
Refereed: Yes
Identification Number: https://doi.org/10.1038/bjc.2012.523
Related URLs:

Share / Export

Statistics